CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)

Systemic Lupus Erythematosus Clinical Trial

— CASTLE  

Official title:

CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE): Studie Zur Detektion Des kardiovaskulären Risikos in Patienten Mit Systemischem Lupus Erythematodes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01520155
• Other study ID #: sleffm001
• Status: Completed
• Phase: N/A
• First received: December 12, 2011
• Last updated: December 20, 2013
• Start date: December 2011
• Est. completion date: December 2012

Study information

• Verified date: December 2013
• Source: Johann Wolfgang Goethe University Hospitals
• Contact: n/a
• Is FDA regulated: No
• Health authority: Ethik-Kommission des Fachbereichs Medizin der Johann Wolfgang Goethe-Universität: Germany
• Study type: Observational

Clinical Trial Summary

The key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three groups of patients will be compared.

Description:

Key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three group of patients will be compared as followed. First group are patients with known systemic Lupus erythematodes without renal affection, second group are patients with known systemic Lupus erythematodes with renal affection and the third group are patients with a non-autoimmun chronic kidney disease

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients with systemic Lupus erythematosus

Exclusion Criteria:

• Patients without systemic Lupus erythematosus

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

Locations

Country	Name	City	State
Germany	Frankfurt University Academic Medical Center	Frankfurt am Main	Hessen

Sponsors (1)

Lead Sponsor	Collaborator
Johann Wolfgang Goethe University Hospitals

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of cardiovascular risk in patients with systemic Lupus Erythematodes	Identification of cardiovascular risk in patients with systemic Lupus Erythematodes	one year	No